A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
about
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Prognostic value of response after upfront therapy for acute GVHDMethotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHDFirst- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.Implications of TNF-α in the pathogenesis and management of GVHDPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Advances in the treatment of acute graft-versus-host disease.Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.Treatment and management of graft-versus-host disease: improving response and survival.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Cutaneous graft-versus-host disease: rationales and treatment options.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Thinking out of the box--new approaches to controlling GVHD.Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.State-of-the-art acute and chronic GVHD treatment.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.The continuing evolution of targeted therapy for inflammatory skin disease.Cellular and molecular mechanisms in graft-versus-host disease.Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management.Oral glutamine supplementation improves intestinal permeability dysfunction in a murine acute graft-vs.-host disease model.The role of infliximab on paracetamol-induced hepatotoxicity in rats.Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease.[Off-label use of infliximab].Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
P2860
Q33886907-997AEFEB-704C-4DB5-B4C2-D95B14E9626AQ33964701-C148E3F4-D125-4F9D-BA39-52C0C89FD481Q34487408-44350617-1116-4545-8F4B-0D7BD97C6446Q34551192-BD171365-02C7-4F0D-AE1E-CEF6C5C6F741Q34974093-A59BD2B6-E2D0-448B-8AB5-472FCF964202Q36113205-59CA40BD-BD6A-4504-8083-7922A1B2D8ADQ36321264-6774EEFE-2413-4AFA-999B-7AB482CF1679Q36370782-1C2B4659-E2F6-42D8-A80A-08FB8D056C76Q37035815-9E6E562B-5FF5-4BAC-857D-211EA852AFD7Q37191057-00926EA5-D1D9-458B-B708-001C30E0D954Q37302887-16A0AC83-CD0B-4D2D-A754-D8499A4F26ECQ37371836-D4F5E1D8-18E7-4AC4-AF2E-03F4AE90B473Q37810286-F7C86CF1-1693-4DFE-A951-4463765B0201Q37851519-5DCC337A-5CF9-4022-A1AC-80E106BE7850Q37853600-54C2BE3A-E77B-4CCC-8A5F-0CAAE54C5DBFQ38066586-6A48F9AC-9B55-4B43-921F-68C1653F3982Q38175862-3FF9271D-341D-4DC6-AC50-4FA02274E53CQ38226527-58C59464-B98F-4BF9-ADC1-8249F2DF5023Q38416371-4D2EEDDD-7244-479B-9B90-93768B015C2AQ38416376-62CFC517-398B-4B17-ABF0-8EB6A7295B57Q38460376-1C626BFF-B079-4A5F-BBA7-208C55B3B843Q38596134-6FAB100D-E2BB-4C72-AC72-FD9AF0CD8BCBQ38661579-911BB363-798B-4F82-ABF4-42D001DA80F6Q38919897-F17ED6DE-A373-48F0-BE7D-F96F502B0409Q43716527-00E563C5-948D-4808-88A9-04D206A1C865Q44654576-D9CBD80F-B6F3-42AF-9236-AFCA33EF907CQ48281486-1F8E0848-7762-4F53-A856-E83DC78D58E0Q54710052-DBD15CF1-D9C4-45E5-BE84-D4118A15963DQ54937398-D4A35DFC-6023-4FE2-AC9D-415B156A0F69Q55386131-C9534A60-4298-4C64-A600-D856B36E992D
P2860
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase III study of inflixima ...... ute graft-versus-host disease.
@ast
A phase III study of inflixima ...... ute graft-versus-host disease.
@en
type
label
A phase III study of inflixima ...... ute graft-versus-host disease.
@ast
A phase III study of inflixima ...... ute graft-versus-host disease.
@en
prefLabel
A phase III study of inflixima ...... ute graft-versus-host disease.
@ast
A phase III study of inflixima ...... ute graft-versus-host disease.
@en
P2093
P2860
P1476
A phase III study of inflixima ...... ute graft-versus-host disease.
@en
P2093
Amin Alousi
Borje Andersson
Chitra Hosing
Cindy Ippoliti
Daniel R Couriel
Elizabeth J Shpall
Issa Khouri
Marcos de Lima
Richard Champlin
Rima Saliba
P2860
P304
P356
10.1016/J.BBMT.2009.08.003
P577
2009-09-25T00:00:00Z